Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas D Walter

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Antimicrobial Agents and Chemotherapy|April 29, 2026
Pretomanid vs delamanid in a bedaquiline-linezolid regimen: efficacy in a high-burden tuberculosis mouse modelJason E Cummings, Lisa K Woolhiser, Vincent Guglielmi, et al.
Frontiers in Pharmacology|December 4, 2025
Correction: Evaluating the efficacy of HRZE-based regimens in a high-burden murine model: a back-translational assessment of rifamycins and moxifloxacin substitutions in tuberculosis treatmentJason E Cummings, Lisa K Woolhiser, Vincent Guglielmi, et al.
Frontiers in Pharmacology|October 1, 2025
Evaluating the efficacy of HRZE-based regimens in a high-burden murine model: a back-translational assessment of rifamycins and moxifloxacin substitutions in tuberculosis treatmentJason E Cummings, Lisa K Woolhiser, Vincent Guglielmi, et al.
Biorxiv : the Preprint Server for Biology|January 9, 2026
Same class, different activity: Delamanid and pretomanid have comparable bactericidal activity but pretomanid potently inhibits <i>Mycobacterium tuberculosis</i> ribosomal rRNA synthesisMatthew J Reichlen, Emmanuel Musisi, Samuel T Tabor, et al.
BMC Infectious Diseases|July 5, 2018
Does discovery of differentially culturable M tuberculosis really demand a new treatment paradigm? Longitudinal analysis of DNA clearance from sputumNicholas D Walter, Camille M Moore, Xavier A Kayigire, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 2, 2013
Prevalence and outcomes of cryptococcal antigenemia in HIV-seropositive patients hospitalized for suspected tuberculosis in UgandaAlfred O Andama, Saskia den Boon, David Meya, et al.
Biorxiv : the Preprint Server for Biology|December 25, 2025
Mind the gap: Understanding discordance between culture- and a non-culture-based measure of bacterial burden in murine tuberculosis treatment modelsSamuel T Tabor, Allan D Friesen, Matthew J Reichlen, et al.
Biorxiv : the Preprint Server for Biology|April 3, 2026
Adaptive immunity shapes baseline physiology of <i>M. tuberculosis</i> in high-dose versus low-dose infection BALB/c mouse drug treatment modelsJo Hendrix, Reem Al Mubarak, Karen Rossmassler, et al.
Scientific Reports|April 10, 2025
70% ethanol preserves mycobacterial RNA from cultures more efficiently than GTC-TCEPLena Krausser, Magalie Van Dyck-Lippens, Ramata Balde, et al.
Antimicrobial Agents and Chemotherapy|January 17, 2025
Emergence of antibiotic-specific <i>Mycobacterium tuberculosis</i> phenotypes during prolonged treatment of miceElizabeth A Wynn, Christian Dide-Agossou, Reem Al Mubarak, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Antimicrobial Agents and Chemotherapy|April 29, 2026
Pretomanid vs delamanid in a bedaquiline-linezolid regimen: efficacy in a high-burden tuberculosis mouse modelJason E Cummings, Lisa K Woolhiser, Vincent Guglielmi, et al.
Frontiers in Pharmacology|December 4, 2025
Correction: Evaluating the efficacy of HRZE-based regimens in a high-burden murine model: a back-translational assessment of rifamycins and moxifloxacin substitutions in tuberculosis treatmentJason E Cummings, Lisa K Woolhiser, Vincent Guglielmi, et al.
Frontiers in Pharmacology|October 1, 2025
Evaluating the efficacy of HRZE-based regimens in a high-burden murine model: a back-translational assessment of rifamycins and moxifloxacin substitutions in tuberculosis treatmentJason E Cummings, Lisa K Woolhiser, Vincent Guglielmi, et al.
Biorxiv : the Preprint Server for Biology|January 9, 2026
Same class, different activity: Delamanid and pretomanid have comparable bactericidal activity but pretomanid potently inhibits <i>Mycobacterium tuberculosis</i> ribosomal rRNA synthesisMatthew J Reichlen, Emmanuel Musisi, Samuel T Tabor, et al.
BMC Infectious Diseases|July 5, 2018
Does discovery of differentially culturable M tuberculosis really demand a new treatment paradigm? Longitudinal analysis of DNA clearance from sputumNicholas D Walter, Camille M Moore, Xavier A Kayigire, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 2, 2013
Prevalence and outcomes of cryptococcal antigenemia in HIV-seropositive patients hospitalized for suspected tuberculosis in UgandaAlfred O Andama, Saskia den Boon, David Meya, et al.
Biorxiv : the Preprint Server for Biology|December 25, 2025
Mind the gap: Understanding discordance between culture- and a non-culture-based measure of bacterial burden in murine tuberculosis treatment modelsSamuel T Tabor, Allan D Friesen, Matthew J Reichlen, et al.
Biorxiv : the Preprint Server for Biology|April 3, 2026
Adaptive immunity shapes baseline physiology of <i>M. tuberculosis</i> in high-dose versus low-dose infection BALB/c mouse drug treatment modelsJo Hendrix, Reem Al Mubarak, Karen Rossmassler, et al.
Scientific Reports|April 10, 2025
70% ethanol preserves mycobacterial RNA from cultures more efficiently than GTC-TCEPLena Krausser, Magalie Van Dyck-Lippens, Ramata Balde, et al.
Antimicrobial Agents and Chemotherapy|January 17, 2025
Emergence of antibiotic-specific <i>Mycobacterium tuberculosis</i> phenotypes during prolonged treatment of miceElizabeth A Wynn, Christian Dide-Agossou, Reem Al Mubarak, et al.
Pageof 6